AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 22, 2014 meeting (pages 3-6; Tab 1)

IV. Secretary’s report (pages 7-8; Tab 2)

V. Old Business (Tab 3)
   A. HMO response to DURB follow-up questions regarding protocols (page 9)
   B. Oxycodone utilization review (page 10)
   C. Atrial fibrillation drugs utilization survey (page 11)
   D. Topical lidocaine (Lidoderm®) utilization report (page 12)

VI. New Business
   A. Protocols review (pages 13-28; Tab 4)
      1. Colony-Stimulating Factors (CSF)
      2. Anti-migraine agents

VII. Informational Highlights/Reports
   2. Summary of DURB Action Items (pages 31-32; Tab 6)
   3. DHS and DHSS Programs Top Drugs Report (pages 33-42; Tab 7)
   4. Medication information: (pages 43-48; Tab 8)
      (a) FDA approves Harvoni® for Hepatitis C
      (b) FDA approves Viekira® Pak for Hepatitis C
      (c) Study: Seniors still given potentially dangerous sedatives
      (d) FDA approves Saxenda® for weight loss